Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An update on the safety of SGLT2 inhibitors
André Scheen
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 4, pp. 295-311
Closed Access | Times Cited: 155

Showing 26-50 of 155 citing articles:

SGLT2 Inhibitors and Safety in Older Patients
Rena Pollack, Avivit Cahn
Heart Failure Clinics (2022) Vol. 18, Iss. 4, pp. 635-643
Closed Access | Times Cited: 22
SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports
Hibathulla Palapra, Subeesh K. Viswam, Vivekanandan Kalaiselvan, et al.
International Journal of Clinical Pharmacy (2022) Vol. 44, Iss. 6, pp. 1425-1433
Closed Access | Times Cited: 19
Safety of sodium‐glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
Mauro Rigato, Gian Paolo Fadini, Angelo Avogaro
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2963-2969
Closed Access | Times Cited: 13
Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy—A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure
Lorenzo Pistelli, Francesca Parisi, Michele Correale, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 1, pp. 379-379
Open Access | Times Cited: 12
Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study
Britney Stottlemyer, Michael C. McDermott, Mackenzie R. Minogue, et al.
Therapeutic Advances in Drug Safety (2023) Vol. 14
Open Access | Times Cited: 11
Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization study
Yilong Lin, Yue Zhang, Songsong Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Managing Diabetes in Older Adults: Current Approaches in Long-Term Care Facilities
Thaer Idrees, Guillermo E. Umpierrez, Sriya Kantipudi, et al.
Current Diabetes Reports (2025) Vol. 25, Iss. 1
Closed Access
Current Evidence on SGLT‐2 Inhibitors in Prediabetes: A Review of Preclinical and Clinical Data
Fariba Pourkarim, Taher Entezari‐Maleki, Haleh Rezaee
The Journal of Clinical Pharmacology (2025)
Closed Access
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review
Kashif Haider, Ankita Pathak, A. Rohilla, et al.
European Journal of Medicinal Chemistry (2019) Vol. 184, pp. 111773-111773
Closed Access | Times Cited: 34
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Lidan Yang, Lin Zhang, He He, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1921-1934
Open Access | Times Cited: 30
<p>SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients</p>
André Scheen
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 2765-2779
Open Access | Times Cited: 29
Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts
Marta Baviera, Stefano Genovese, Vito Lepore, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 7, pp. 1484-1495
Closed Access | Times Cited: 27
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet
Shufei Zeng, Denis Delić, Chang Chu, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112606-112606
Open Access | Times Cited: 24
Update on the management of diabetes in long-term care facilities
Thaer Idrees, Iris A. Castro-Revoredo, Alexandra L. Migdal, et al.
BMJ Open Diabetes Research & Care (2022) Vol. 10, Iss. 4, pp. e002705-e002705
Open Access | Times Cited: 18
SGLT2 Inhibitors’ Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review
Sajad Khiali, Mohammadreza Taban Sadeghi, Parvin Sarbakhsh, et al.
The Journal of Clinical Pharmacology (2023) Vol. 63, Iss. 12, pp. 1307-1323
Closed Access | Times Cited: 10
SGLT2 inhibitor use in the management of feline diabetes mellitus
Audrey K. Cook, Ellen N. Behrend
Journal of Veterinary Pharmacology and Therapeutics (2024)
Open Access | Times Cited: 3
Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
André Scheen
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 3, pp. 243-256
Closed Access | Times Cited: 27
SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
André Scheen
Diabetes & Metabolism (2020) Vol. 46, Iss. 5, pp. 343-344
Open Access | Times Cited: 25
Careful use to minimize adverse events of oral antidiabetic medications in the elderly
André Scheen
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 16, pp. 2149-2165
Closed Access | Times Cited: 23
Sulphonylureas in the management of type 2 diabetes: To be or not to be?
André Scheen
Diabetes Epidemiology and Management (2021) Vol. 1, pp. 100002-100002
Open Access | Times Cited: 22
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Munteanu Madalina Andreea, Swarnkar Surabhi, Răzvan-Ionuț Popescu, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 742-742
Open Access | Times Cited: 9
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
André Scheen
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 4, pp. 271-282
Closed Access | Times Cited: 9
Calorie restriction mimetic drugs could favorably influence gut microbiota leading to lifespan extension
Tomoya Shintani, Hideya Shintani, Masashi Sato, et al.
GeroScience (2023) Vol. 45, Iss. 6, pp. 3475-3490
Open Access | Times Cited: 8
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
André Scheen
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1053-1062
Closed Access | Times Cited: 8

Scroll to top